MediumEndocrinologyType 2 diabetes with CKD and CVDau-amcau-racp
A 58‑year‑old man with type 2 diabetes for 12 years, established coronary artery disease and albuminuric chronic kidney disease (eGFR 45 mL/min/1.73 m², ACR 40 mg/mmol) is on metformin and maximal ACE inhibitor therapy. His HbA1c is 60 mmol/mol (7.6%). According to contemporary guidance, which additional glucose‑lowering therapy is preferred to improve both renal and cardiovascular outcomes?